$TARS earnings report

Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year. AlphAI read Tarsus Pharmaceuticals's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readTARS · Third Quarter 2026 · ended September 30, 2026

Tarsus Reports Third Quarter 2026 Financial Results Generated record XDEMVY net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year

✓Strong quarter

XDEMVY net product sales rose approximately 64% year-over-year to a record $194.6 million and gross margins remained approximately 93%, while reported net loss expanded primarily because of $632.2 million of acquired in-process R&D expense related to the iRenix and Alkeus acquisitions.

Revenue
$195M
XDEMVY
$195M
approximately 64% y/y
Gross margin · GAAP
approximately 93%
EPS · GAAP
$(14.40)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 product sales, netGAAP$194.6M–approximately 64%
Q3 2026 total revenuesGAAP$194.6M––
Q3 2026 cost of salesGAAP$13.9M––
Q3 2026 gross marginGAAPapproximately 93%––
Q3 2026 research and development expensesGAAP$44.2M––
Q3 2026 acquired in-process research and development expensesGAAP$632.2M––
Q3 2026 selling, general and administrative expensesGAAP$168M––
Q3 2026 change in fair value of contingent considerationGAAP−$1.6M––
Q3 2026 total operating expensesGAAP$856.7M––
Q3 2026 loss from operations before other income (expense)GAAP−$662.1M––
Q3 2026 interest incomeGAAP$3.78M––
Q3 2026 interest expenseGAAP−$2.19M––
Q3 2026 other income (expense), netGAAP$91K––
Q3 2026 total other income (expense), netGAAP−$1.60M––
Q3 2026 provision for income taxesGAAP−$4.64M––
Q3 2026 net lossGAAP$668.3M––
Q3 2026 net loss per share, basic and dilutedGAAP$(14.40)––
Q3 2026 weighted-average shares outstanding, basic and dilutedGAAP46,421,382––
Q3 2026 comprehensive lossGAAP−$668.7M––
Nine months ended September 30, 2026 product sales, netGAAP$513.9M––
Nine months ended September 30, 2026 license fees and collaboration revenueGAAP$16.7M––
Nine months ended September 30, 2026 total revenuesGAAP$530.5M––
Nine months ended September 30, 2026 cost of salesGAAP$35.4M––
Nine months ended September 30, 2026 gross marginGAAPapproximately 93%––
Nine months ended September 30, 2026 research and development expensesGAAP$97.6M––
Nine months ended September 30, 2026 acquired in-process research and development expensesGAAP$632.2M––
Nine months ended September 30, 2026 selling, general and administrative expensesGAAP$455.1M––
Nine months ended September 30, 2026 net lossGAAP$693.9M––
Nine months ended September 30, 2026 net loss per share, basic and dilutedGAAP$(15.67)––
Cash and cash equivalents as of September 30, 2026GAAP$136.5M––
Marketable securities as of September 30, 2026GAAP$173.1M––
Cash, cash equivalents and marketable securities as of September 30, 2026GAAP$309.6M––
Long-term debt, net as of September 30, 2026GAAP$72.94M––
Contingent consideration, non-current as of September 30, 2026GAAP$85.69M––

Segments

SegmentRevenueq/qy/y
XDEMVYHigher volume and improvements in the gross-to-net discounts.$194.6M–approximately 64%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

What drove it

  • XDEMVY product sales were driven by higher volume and improvements in the gross-to-net discounts.
  • The average number of Eye Care Professionals prescribing XDEMVY at least daily increased approximately 20% from the beginning to the end of the third quarter.
  • Direct-to-consumer initiatives drove a 75% increase in high-value actions, and the company reported a higher prescription conversion than last year.
  • Refills accounted for approximately 20% of XDEMVY prescriptions in the third quarter.
  • The company completed the acquisitions of iRenix Medical and Alkeus Pharmaceuticals.
  • Nine-month license fees and collaboration revenue included a $15.0 million regulatory milestone from the China out-license partner and $1.7 million of required China withholding tax.

Concerns

  • Q3 acquired in-process R&D expense was $632.2 million, consisting of $81.0 million related to iRenix and $551.2 million related to Alkeus.
  • Q3 SG&A expense increased to $168.0 million from $108.6 million, including $23.5 million of Alkeus transaction-related and integration costs and $11.7 million of commercial and marketing costs.
  • Q3 R&D expense increased to $44.2 million from $16.3 million, including $13.7 million attributable to the Alkeus acquisition.
  • The company recorded a $4,642 (In thousands) provision for income taxes in Q3 2026, compared with none in Q3 2025.
  • No financial outlook was provided in the release.

What to watch

  • Topline data from the Phase 2 Kore trial for TP-04 are expected in the first half of 2027.
  • Topline results from the Phase 2 Calliope trial for TP-05 are expected in the first half of 2027 and are anticipated to support a Phase 3-ready package.
  • The Phase 3 Comfort study for IRX-101 is planned to initiate in the first half of 2027, with topline results expected in 2028.
  • Topline results from the global Phase 3 Northstar trial for gildeuretinol are expected in 2029.
  • Progress in XDEMVY prescribing frequency, prescription conversion, refills, and direct-to-consumer activity.

Balance sheet and cash flow

  • As of September 30, 2026, cash, cash equivalents and marketable securities were $309.6 million.
  • Cash and cash equivalents were $136,530 (In thousands) as of September 30, 2026, compared with $183,641 (In thousands) at December 31, 2025.
  • Marketable securities were $173,082 (In thousands) as of September 30, 2026, compared with $233,627 (In thousands) at December 31, 2025.
  • Long-term debt, net was $72,935 (In thousands) as of September 30, 2026, compared with $72,438 (In thousands) at December 31, 2025.
  • No cash flow statement was included in the filing text.

Analysis

Tarsus delivered record third-quarter XDEMVY net product sales of $194.6 million, up approximately 64% year-over-year from $118.7 million. Management attributed the increase to higher volume and improvements in gross-to-net discounts. Commercial indicators also showed broader use: the average number of Eye Care Professionals prescribing XDEMVY at least daily increased approximately 20% during the quarter, direct-to-consumer initiatives drove a 75% increase in high-value actions, and refills represented approximately 20% of prescriptions.

The gross-profit profile remained stable, with gross margins approximately 93% in both the 2026 and 2025 third quarters. However, operating costs increased substantially. R&D was $44.2 million versus $16.3 million, while SG&A was $168.0 million versus $108.6 million. The expense increase included Alkeus acquisition-related costs, expanded commercial and marketing activity for XDEMVY, patient support and corporate functions, and additional personnel.

Reported GAAP results were dominated by acquisition accounting. Tarsus expensed $632.2 million of acquired in-process R&D, including $81.0 million for iRenix and $551.2 million for Alkeus, because the acquired IPR&D had no alternative future use. This drove a Q3 net loss of $668.3 million, compared with $12.6 million in the prior-year period, and a basic and diluted net loss per share of $(14.40), compared with $(0.30).

The company reported $309.6 million of cash, cash equivalents and marketable securities as of September 30, 2026, alongside $72,935 (In thousands) of long-term debt, net, and $85,689 (In thousands) of non-current contingent consideration. The filing provided no financial guidance. Operational attention shifts to continued XDEMVY commercial expansion and the pipeline calendar, including TP-04 and TP-05 topline data expected in the first half of 2027, planned initiation of the IRX-101 Phase 3 Comfort study in the first half of 2027, and gildeuretinol Phase 3 Northstar topline results expected in 2029.

Management, verbatim

XDEMVY has shown what that focus can achieve. In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started.

Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus

Not in the filing

stated, not guessed
  • Financial revenue, expense, margin, tax-rate, earnings, or cash-flow guidance
  • Non-GAAP financial metrics and reconciliations
  • Operating cash flow
  • Free cash flow
  • Gross profit
  • Share repurchases
  • Dividends
  • Q3 2026 prior-quarter comparisons
  • Segment reporting beyond XDEMVY product sales
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readTARS · second quarter 2026 · ended June 30, 2026

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

✓Strong quarter

XDEMVY net product sales reached $173.9 million, more than 69% above the prior-year period, while the company increased full-year 2026 XDEMVY net product sales guidance to $685-705 million. The net loss narrowed to $18.6 million despite higher commercial, DTC, patient-support, R&D, and corporate spending.

Gross margin · other
93%
EPS · other
$(0.43)
full-year 2026 outlook
XDEMVY net product sales of $685-705 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
XDEMVY net product salesother$173.9M–more than 69%
Cost of salesother$12.1M––
Gross marginsother93%––
Research and development expensesother$31M––
R&D non-cash stock-based compensation expenseother$3M––
Selling, general and administrative expensesother$150.7M––
SG&A non-cash stock-based compensation expenseother$10.1M––
Net lossother$18.6M––
Basic and diluted net loss per shareother$(0.43)––
Cash, cash equivalents and marketable securitiesother$449.7M––
Year-to-date product salesother$319.3M––
Year-to-date license fees and collaboration revenueother$16.7M––
Year-to-date cost of salesother$21.5M––
Year-to-date gross marginsother93%––
Year-to-date research and development expensesother$53.4M––
Year-to-date R&D non-cash stock compensation expenseother$6M––
Year-to-date selling, general and administrative expensesother$287.1M––
Year-to-date SG&A non-cash stock compensation expenseother$18.8M––
Year-to-date net lossother$25.5M––
Year-to-date basic and diluted net loss per shareother$(0.59)––

full-year 2026 outlook

  • RevenueXDEMVY net product sales of $685-705 million

What drove it

  • Product sales growth was driven by higher volume and improvements in the gross-to-net discount.
  • The number of eye care professionals prescribing XDEMVY five or more times per week has doubled year-over-year.
  • Direct-to-consumer initiatives continued to contribute to prescription growth and awareness.
  • XDEMVY.com website engagement increased by more than 30% since the start of both new initiatives, with high-value actions up 19%.
  • Unaided awareness of Demodex blepharitis was approximately 30% versus 2% of patients surveyed at the beginning of the Company’s DTC campaign.
  • Year-to-date license fees and collaboration revenue included a $15.0 million regulatory milestone under the China out-license and $1.7 million of required China withholding tax associated with this milestone.

Concerns

  • Second-quarter SG&A expenses were $150.7 million, compared to $103.0 million for the same period in 2025, reflecting commercial and marketing costs including DTC advertising, patient support, information technology, legal, professional services, and personnel additions.
  • Second-quarter R&D expenses were $31.0 million, compared to $15.6 million for the same period in 2025, including $8.0 million of TP-05 program expenses related to the Calliope trial.
  • The company reported a second-quarter net loss of $18.6 million.
  • The acquisition of Alkeus Pharmaceuticals remains subject to the announced agreement, while the filing identifies ALK-001 as an investigational therapy with a Phase 3 clinical program.

What to watch

  • Topline data from the Phase 2 KORE trial of TP-04 is expected in the first half of 2027.
  • Topline data from the Phase 2 Calliope trial of TP-05 is expected in the first half of 2027, with the potential to support a Phase 3-ready package.
  • The company anticipates initiating the Phase 3 COMFORT trial of IRX-101 in the first half of 2027, with topline results expected in 2028.
  • Execution against full-year 2026 XDEMVY net product sales guidance of $685-705 million.
  • Progress of the announced acquisition of Alkeus Pharmaceuticals and its ALK-001 Phase 3 program for Stargardt disease.

Balance sheet and cash flow

  • As of June 30, 2026, cash, cash equivalents and marketable securities were $449.7 million.
  • Priced $125 million private placement financing which included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors.

Analysis

Tarsus reported a record commercial quarter for XDEMVY, with net product sales of $173.9 million versus $102.7 million in the same period in 2025. Management attributed the increase to higher volume and improvements in the gross-to-net discount. Adoption indicators also remained favorable: the number of eye care professionals prescribing XDEMVY five or more times per week doubled year-over-year, while direct-to-consumer initiatives contributed to prescription growth and awareness.

Product economics remained high margin, with gross margins of 93% compared with 94% in the same period in 2025. Cost of sales was $12.1 million, compared with $6.2 million, reflecting XDEMVY manufacturing costs, royalties on net product sales, and amortization of milestone payments to the company’s licensor. The filing raised full-year 2026 XDEMVY net product sales guidance to $685-705 million.

Commercial investment rose materially. SG&A expenses were $150.7 million compared with $103.0 million, driven principally by $21.2 million of commercial and marketing costs including DTC advertising, $19.5 million of patient-support, information-technology, legal, and professional-services costs, and $6.7 million of payroll and personnel-related costs. R&D expenses increased to $31.0 million from $15.6 million, including $8.0 million of TP-05 program expenses and $3.1 million of TP-03 program expenses. Despite these investments, net loss narrowed to $18.6 million from $20.3 million, and basic and diluted net loss per share improved to $(0.43) from $(0.48).

For the first six months of 2026, product sales were $319.3 million compared with $181.0 million in the same period in 2025. The company also reported $16.7 million of license fees and collaboration revenue from its China out-license partner, including a $15.0 million regulatory milestone and $1.7 million of required China withholding tax recorded on a gross basis. Year-to-date net loss narrowed to $25.5 million from $45.5 million, while year-to-date SG&A increased to $287.1 million and R&D increased to $53.4 million.

Tarsus ended June 30, 2026 with $449.7 million of cash, cash equivalents and marketable securities and announced a $125 million private placement financing. Strategically, the company completed the iRenix Medical acquisition, is advancing TP-04, TP-05, and IRX-101, and entered into an agreement to acquire Alkeus Pharmaceuticals and ALK-001. The next disclosed clinical milestones are TP-04 and TP-05 topline data in the first half of 2027, followed by anticipated IRX-101 Phase 3 initiation in the first half of 2027 and expected topline results in 2028.

Management, verbatim

XDEMVY delivered another record quarter, reflecting strong underlying demand and commercial execution.

Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus

This performance gives us the commercial foundation and financial strength to remain intensely focused on growing XDEMVY while strategically investing in our next wave of growth.

Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus

Not in the filing

stated, not guessed
  • Total revenue for the second quarter 2026 and the same period in 2025.
  • Total revenue for the year-to-date 2026 period and the same period in 2025.
  • Operating income or loss.
  • Operating cash flow.
  • Free cash flow.
  • Debt balance.
  • Share repurchases and dividends.
  • Prior-quarter comparisons for reported metrics.
  • Full-year 2026 gross margin, operating-expense, and tax-rate guidance.
  • Prior outlook figures for comparison with actual results.
  • Reported operating segments and segment revenue.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about TARS earnings dates

When is Tarsus Pharmaceuticals's next earnings date?
AlphAI has no date for TARS yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.